Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
90 results about "Biological therapies" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method and apparatus to modulate cellular regeneration post myocardial infarct
InactiveUS20050288721A1Easy to adjustModulate tissue growthMedical devicesPressure infusionCardiac muscleWorkload
A system delivers cardiac pacing therapy and chemical and / or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a cardiac rhythm management (CRM) device to deliver pacing pulses to enhance the effects of the one or more agents by altering myocardial wall stress and cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable CRM device.
Owner:CARDIAC PACEMAKERS INC
Devices and methods for interstitial injection of biologic agents into tissue
The current invention discloses a method for treating infracted / ischemic injury to a myocardium by injecting a substance into the myocardium. The injected substance helps to prevent negative adaptive remodeling by providing mechanical reinforcement or mechanical reinforcement combined with biological therapy. A number of substances for injection are disclosed, including multi component substances such as platelet gel, and other substances. The substances disclosed may contain additives to augment / enhance the desired effects of the injection. The invention also discloses devices used to inject the substances. The devices can include means for ensuring needles do not penetrate beyond a desired depth into the myocardium. The devices can also include needles having multiple lumens such that the components of the platelet gel will be combined at the injection site and begin polymerization in the myocardium.
Owner:MEDTRONIC INC
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
InactiveUS20060030594A1Prevent proliferationBiocidePeptide/protein ingredientsCompound (substance)Radiation therapy
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Owner:CELGENE CORP
Combination therapy for treating, preventing or managing proliferative disorders and cancers
InactiveUS20040067953A1Improve efficiencyImprove toleranceBiocideHeavy metal active ingredientsCancer preventionBiologically-Based Therapy
The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies.
Owner:SIGNAL PHARMA LLC
Methods and Systems for Treating Injured Cardiac Tissue
InactiveUS20070014784A1Simple processReduce riskDiagnosticsInfusion syringesAutologous plateletThinning
Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing composition can thicken the wall of a heart, or act to prevent further thinning and thereby provide resistance against further remodeling. A number of compositions are disclosed, including multi-component substances such as autologous platelet gel, and other substances. The compositions disclosed can contain additives to augment / enhance the desired effects of the injection.
Owner:MEDTRONIC VASCULAR INC
Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
InactiveUS20060036126A1Good effectPromote tissue growthControl devicesBlood pumpsCardiac muscleVentricular assistance
A system delivers combined ventricular assist device (VAD) therapy and chemical and / or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a VAD to enhance the effects of the one or more agents by reducing myocardial wall stress and the overall cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable VAD for long-term use in a patient.
Owner:CARDIAC PACEMAKERS INC
Methods and Systems for Treating Injured Cardiac Tissue
InactiveUS20070042016A1Simple processReduce riskInfusion syringesSurgical needlesAutologous plateletThinning
Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing composition can thicken the wall of a heart, or act to prevent further thinning and thereby provide resistance against further remodeling. A number of compositions are disclosed, including multi-component substances such as autologous platelet gel, and other substances. The compositions disclosed can contain additives to augment / enhance the desired effects of the injection.
Owner:MEDTRONIC VASCULAR INC
Devices and methods for interstitial injection of biologic agents into tissue
The current invention discloses a method for treating infracted / ischemic injury to a myocardium by injecting a substance into the myocardium. The injected substance helps to prevent negative adaptive remodeling by providing mechanical reinforcement or mechanical reinforcement combined with biological therapy. A number of substances for injection are disclosed, including multi component substances such as platelet gel, and other substances. The substances disclosed may contain additives to augment / enhance the desired effects of the injection. The invention also discloses devices used to inject the substances. The devices can include means for ensuring needles do not penetrate beyond a desired depth into the myocardium. The devices can also include needles having multiple lumens such that the components of the platelet gel will be combined at the injection site and begin polymerization in the myocardium.
Owner:MEDTRONIC INC
Methods and systems for treating injured cardiac tissue
InactiveUS20070093748A1Simple processReduce riskElectrotherapySurgical needlesAutologous plateletThinning
Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing composition can thicken the wall of a heart, or act to prevent further thinning and thereby provide resistance against further remodeling. A number of compositions are disclosed, including multi-component substances such as autologous platelet gel, and other substances. The compositions disclosed can contain additives to augment / enhance the desired effects of the injection.
Owner:MEDTRONIC VASCULAR INC
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
![Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders](https://images-eureka.patsnap.com/patent_img/408a1ac5-24ef-4a6a-983b-785f6d97d096/US20080063642A1-20080313-D00000.png "Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders")
![Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders](https://images-eureka.patsnap.com/patent_img/408a1ac5-24ef-4a6a-983b-785f6d97d096/US20080063642A1-20080313-D00001.png "Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders")
![Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders](https://images-eureka.patsnap.com/patent_img/408a1ac5-24ef-4a6a-983b-785f6d97d096/US20080063642A1-20080313-D00002.png "Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders")
Owner:SUNESIS PHARMA INC
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
![Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders](https://images-eureka.patsnap.com/patent_img/28a10672-fdc4-4e33-8f21-8d1ac3c58954/US20110008371A1-20110113-C00001.png "Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders")
Owner:SUNESIS PHARMA INC
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Application of lactobacillus plantarum in reducing blood fat and assisting fat-reducing
InactiveCN103598594AStrong bile salt toleranceLower levelMilk preparationMulti-step food processesSerum igeMicroorganism
The invention relates to an application of lactobacillus plantarum in preparation of food, health food, a health product or a medicine with a function of reducing blood fat or assisting fat-reducing. The collection number of the lactobacillus plantarum is CGMCC No.8198. the lactobacillus plantarum was collected in China General Microbiological Culture Collection Center (CGMCC) on Sep. 17, 2013. The address is 1 Beichen West Road, Chaoyang District, Beijing. The strain achieves the effect of reducing blood fat by reducing the level of serum cholesterol, triglyceride and low-density lipoprotein cholesterin. L.plantarum CGMCC No.8198 and its fermented products also play a role in controlling and reducing weight, and have an effect of assisting fat-reducing. The invention provides a biological therapy for effectively reducing serum cholesterol and assisting fat-reducing. The biological therapy has long-term eating safety and has a considerable application prospect.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Polyamine micromolecular developer, production method and application thereof
InactiveCN102442996AReduce intakeExcellent treatment monitoringOrganic chemistryIn-vivo radioactive preparationsAlkaneApoptosis
The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
InactiveUS20070208057A1Preventing and prolonging their recurrenceLengthening time of remissionBiocideSenses disorderSide effectRadical radiotherapy
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of thalidomide. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Combination therapy for treating or managing acute myelocytic leukemia
InactiveUS20070149571A1Improve efficiencyImprove toleranceHeavy metal active ingredientsBiocideCancer preventionRadical radiotherapy
Owner:SIGNAL PHARMA LLC
Microfluidic tissue model
ActiveUS20150301027A1Bioreactor/fermenter combinationsBiological substance pretreatmentsShear rateOrganism
The present disclosure describes systems and methods for mimicking body tissue and the function thereof. The mimicked body tissue can include kidney tissue, the blood brain barrier, and other tissues. In some implementations, the systems described herein are used to test the impact of controlled factors on the tissue. The controlled factors can include flow rates, shear rates, and test chemicals (e.g., therapeutics and toxins). In some implementations, the system and methods are used to test pharmaceutical and biological therapies, characterize healthy or diseased tissue, and observe phenomena of the tissue in vitro.
Owner:CHARLES STARK DRAPER LABORATORY
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
InactiveUS20050234017A1Preventing and prolonging their recurrenceLengthening time of remissionAntibacterial agentsOrganic active ingredientsSide effectBULK ACTIVE INGREDIENT
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Owner:CELGENE CORP
Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
InactiveUS7828711B2Assists the heart in blood pumpingGood effectControl devicesBlood pumpsCardiac muscleVentricular assistance
A system delivers combined ventricular assist device (VAD) therapy and chemical and / or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a VAD to enhance the effects of the one or more agents by reducing myocardial wall stress and the overall cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable VAD for long-term use in a patient.
Owner:CARDIAC PACEMAKERS INC
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable of ruse in methods of the invention are also disclosed.
Owner:CELGENE CORP
SiO2/Au nano material with nucleocapsid structure-biological protein medicament complex and preparation method thereof
InactiveCN101411879AGood treatment effectPacked tightlyInorganic non-active ingredientsAntineoplastic agentsPolyethylene glycolTherapeutic effect
The invention relates to a composite of SiO2Au nuclear shell structure nano material and biological protein medicament. The composite is prepared through grafting the SiO2Au nuclear shell structure nano material with the biological protein medicament by Au-S bond, and closing rest non-active sites of the SiO2Au nuclear shell structure nano material by sulphane polyethylene glycol. A preparation method comprises the following steps: (1) making amino polyethylene glycol and 2-imino sulphane according to a molar ratio of 1 to 1 reacted in potassium carbonate solution for 1 hour, dialyzing and purifying the reagents by secondary distilled water, and obtaining the sulphane polyethylene glycol; and (2) mixing the SiO2Au nuclear shell structure nano material, the biological protein medicament and the 2-imino sulphane in the potassium carbonate solution, standing over night, adding the mixture into the sulphane polyethylene glycol obtained in step (1) for reaction under the condition of weak alkali buffer solution, so as to obtain the composite. The composite compounds physical therapy of inorganic nano particles and biological therapy function of protein medicament, remarkably improves treatment effect for tumor, and can be used a new anticancer medicament.
Owner:JINAN UNIVERSITY
Methods and compositions using immune regulative compound for treatment and management of cancers and other diseases
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Inhibition of hepatitis B virus (HBV) replication by RNA interference
ActiveUS7067249B2Inhibit expressionObstruction is producedSugar derivativesMicrobiological testing/measurementMessenger RNARadiation therapy
The present invention relates to the inhibition of Hepatitis B virus (HBV) replication by RNA molecules of the present invention. Specifically, the RNA molecules of the present invention are double-stranded ribonucleic acid molecules (dsRNA). Specifically, the invention relates to small interfering RNAs (siRNA) which are double-stranded RNAs that direct the sequence-specific degradation of messenger RNA in mammalian cells. The invention relates to development of a new anti-HBV therapy by inhibition of Hepatitis B Virus (HBV) replication using stably-expressed short hairpin RNAs (shRNA), which degrade HBV pregenomic RNA and message RNAs. Included are methods of treatment of cancer by the administration of RNA molecules of the present invention in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, biological therapies / immunotherapies and / or radiation therapies.
Owner:THE UNIVERSITY OF HONG KONG
Immune regulation and biological therapeutic function of benzo-isoselenazole derivatives
InactiveCN1511834AEnhance immune functionShows anti-inflammatoryAntibacterial agentsSugar derivativesBiological therapiesImmune regulation
Owner:北京大学药学院
'Heat shock protein special extraction kit' for biological therapy
InactiveCN1640887ANot autoimmuneImprove securityPeptide/protein ingredientsPeptide preparation methodsAntigenChromatographic column
The present invention relates to one kind of specific heat shock protein extracting kit, and the extracting kit consists of heat shock protein affinity resin or heat shock protein affinity chromatographic column and may have matched mother liquid for affinity chromatography. The present invention aims at extracting heat shock protein or heat shock protein-polypeptide complex conveniently, fast, effectively and specifically from tissue or cell. The heat shock protein-polypeptide complex antigen extracted with the heat shock protein extracting kit is used in preventing and treating diseases caused by self cell mutation, foreign pathogen infection, autoimmune deficiency, etc.
Owner:BEIJING ZHONGTIANKANGTAI BIOTECH
Application of ferroferric oxide as photo-thermal sensitive material
InactiveCN103055312AExcellent photothermal performanceAchieve specific killingEnergy modified materialsIn-vivo testing preparationsSide effectCytotoxicity
The invention discloses application of ferroferric oxide as a photo-thermal sensitive material. According to the application, ferroferric oxide is radiated by near-infrared light to generate heat and is irradiated by laser with the wavelength of 700-2000nm; Fe3O4 is found to have a favorable photo-thermal effect for the first time and is a potential photo-thermal sensitive agent; the Fe3O4 has a certain application prospect in the aspect of photo-thermal conversion, in particular to the aspect of biological therapy; in addition, the Fe3O4 has remarkable photo-thermal effect and biological therapy effect; specific cytotoxicity of tumor can be realized by irradiating the Fe3O4 for five minutes; after treatment, the tumor is completely removed; the Fe3O4 has no remarkable influence on normal tissues; relative to treatment methods such as operation and chemotherapy, the Fe3O4 is remarkable in curative effect and small in toxic or side effect; and meanwhile, the Fe3O4 integrates various special functions such as magnetic targeting and magnetic resonance imaging, so that the Fe3O4 has broad application prospect in aspects of clinical diagnosis and treatment.
Owner:ZHEJIANG UNIV
Construction method and application of double-target-spot DNA (Deoxyribonucleic Acid) nano therapy system
ActiveCN108721634AStable structureThe synthesis method is simpleAntibacterial agentsPeptide/protein ingredientsSingle strandBiomedicine
The invention belongs to the technical field of biomedicines and in particular relates to a construction method and application of a double-target-spot DNA (Deoxyribonucleic Acid) nano therapy system.The construction method comprises the following steps: dissolving six single-stranded linear-chain DNA into an in-vitro buffer salt solution; carrying out annealing and self-assembling to form a DNAtetrahedron solution; adding crosslinking agent Sulfo-SMCC powder into a 5'-end C6 amino modified ssDNA solution; reacting at room temperature for 2h; removing an unreacted crosslinking agent and thenadding polypeptide powder; reacting at the room temperature for 12h and removing excessive polypeptide to obtain ssDNA-peptide; adding the ssDNA-peptide into the DNA tetrahedron solution, so as to finish construction of the double-target-spot DNA nano therapy system. According to the construction method provided by the invention, a constructed DNA tetrahedron carrier has a stable structure; aftera medicine is loaded on the carrier, the stability of a polypeptide medicine can be improved; the double-target-spot DNA nano therapy system has relatively strong targeting performance and mainly express a biological therapy effect through regulating and controlling a cell signal path.
Owner:ZHENGZHOU UNIV
Intelligent macrophage tumor targeting therapy system and preparation method and application thereof
ActiveCN109620956AGrowth inhibitionProlong lifePhotodynamic therapyInorganic non-active ingredientsTumor targetSide effect
The invention relates to a macrophage tumor targeting therapy system combining a photothermal therapy effect and photo-thermally responsive biotherapeutic factor release and preparation and application thereof. The unique spatial and temporal selectivity of the macrophage tumor targeting therapy system can direct at a variety of solid malignant tumors, combines tumor photo-thermal therapy with biological therapy to achieve the local targeted comprehensive treatment of the tumors and reduce the toxic and side effects of traditional treatment caused by an off-target effect. The macrophage targeting tumor system can effectively inhibit the tumor growth of mice and prolong the survival time of the tumor-bearing mice, is an excellent tumor-targeting biological preparation and has great clinicalconversion application prospects.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com